 CHARLOTTESVILLE, VA ACCESSWIRE December 16, 2019 Adial Pharmaceuticals, Inc. NASDAQ:ADIL; ADILW, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received a Notice of Allowance for the issuance of a patent by the United States Patent and Trademark Office USPTO, titled: Serotonin Transporter Gene and Treatment of Alcoholism. This patent addresses a method of treating alcohol use disorder AUD in patients with a specific genetic biomarker in the serotonin transporter gene by administering the Companys investigational new drug product, AD04, a 5-HT3 antagonist, to patients with the TT genotype. 